Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
about
The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Exon skipping of FcεRIβ eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy.Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous.Topically applied manganese-porphyrins BMX-001 and BMX-010 display a significant anti-inflammatory response in a mouse model of allergic dermatitis.Review of Atopic Dermatitis and Topical Therapies.A novel therapeutic paradigm for patients with extensive alopecia areata.Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.Drug Repurposing to treat Asthma and Allergic Disorders: Progress and Prospects.Chronic Pruritus: Current and Emerging Treatment Options.Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system.Hypochlorous acid is antipruritic and anti-inflammatory in a mouse model of atopic dermatitis.Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.Translational Animal Models of Atopic Dermatitis for Preclinical Studies.Efficacy of tofacitinib in treatment of alopecia universalis in two patients.Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
P2860
Q33890805-7195742A-04E3-4CD5-8AA2-1C1F750010FFQ37493198-9EF551C5-D759-43A5-A53B-EDC983B0C4B0Q38708002-32E7556F-DEA6-446C-9102-BD85841FF501Q38742280-BC075AE7-FFF9-4767-8401-80B2A21E615CQ38744304-06DDA83D-0888-44A2-A1CA-4907F46256E8Q38831003-736633C0-A66A-49E9-A4EA-C4FCF51E7BB9Q39055724-636F6C20-BFF3-446D-A613-CA228EB67C27Q39150081-1AC6CA4E-7815-405C-8D8F-8A90C4215EFAQ39156148-609DB346-DD4E-4C63-9C07-5884DBAA67EAQ41912557-7455E8E5-6CA4-4861-95ED-EFAD1C52C44FQ44876149-2A9DB9DE-1DE4-4D74-B9CB-3263CBB7980DQ51637913-B5DDA467-153F-4EA0-96E7-F261B269188DQ53257382-FD5ED3B8-7B27-4072-A112-A76968D7F74EQ54189934-08260975-A360-42C8-88D9-F83828D6169CQ55396890-E18B0EA9-0D17-4C50-8733-6B5B639D3233Q55517994-903600E4-C70B-4C53-83B8-40F8A40A6A93
P2860
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@en
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@nl
type
label
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@en
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@nl
prefLabel
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@en
Topically Administered Janus-K ...... Model of Allergic Dermatitis.
@nl
P2093
P356
P1476
Topically Administered Janus-K ...... a Model of Allergic Dermatitis
@en
P2093
Elizabeth Cook
Sarah Ehling
Tomoki Fukuyama
P304
P356
10.1124/JPET.115.223784
P407
P577
2015-07-09T00:00:00Z